EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-05-15
Management highlights
• Financial performance: Q1 2025 revenues $4.9M, up 43% YOY. Adjusted EBITDA improved by 92%, cash use in operations improved by 93%. • Seasonal impact: Q1 saw sequential decline due to typical healthcare seasonal patterns like insurance plan reset affecting test volumes. • Pathology division: Test volume up 46%, revenue up 53%, 11 new physicians, margins improved from 24% to 42% YOY. • Medicare reimbursement: MolDx approval for NGS testing to boost revenue/cash by ~$250k per quarter. • Product division: Onboarded 1 new customer, launched 2 panels, pipeline for Q2, FDA ruling uncertainty resolved in March. • Non-recurring impacts: Received ~$1.1M from Change Healthcare and ~$400k COVID relief funds.
Segment performance
Pathology Services division: Q1 2025 revenue was $4.9 million, up 43% year-over-year. Test volume increased 46% and revenue grew 53% year-over-year. 11 new physicians began utilizing services. Gross margins increased due to volume and scale. Product division: Onboarded 1 new customer, launched 2 new diagnostic panels, 2 customers began evaluation for 4 additional panels. Revenue for Q1 2025 was $4.9 million, with Pathology Services contributing significantly and Product division showing pipeline growth.
Guidance
• Anticipate rebound in Q2 and return to positive cash flow in Q2 or Q3. • Expect revenue growth to continue in Q2 and accelerate in H2, particularly on Product side. • Product division expects order volumes to increase steadily in Q2 and beyond. • Pathology division expects gross margins and contributions to improve with continued volume increases.
Risks
• Seasonal pressures in healthcare leading to quarter-over-quarter revenue declines. • Uncertainty around FDA ruling on Laboratory Developed Tests previously causing prospective customers to delay adoption, though resolved in March.
Q&A highlights
Q: Operator: The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.
A: Operator: The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | — | — | — |
| Revenue | — | — | — | — |
Transcript
May 15, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.